Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate families about protection against a serious respiratory syncytial virus (RSV) lung infection

艾美奖获奖女演员、企业家兼母亲可可·帕尔默与赛诺菲合作，帮助家庭了解如何预防严重的呼吸道合胞病毒（RSV）肺部感染

BEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, a leading cause of hospitalization among babies under 1 year of age

数百万家长选择 BEYFORTUS，以帮助保护他们的婴儿免受严重的呼吸道合胞病毒（RSV）肺部感染，这是导致1岁以下婴儿住院的主要原因。

Campaign encourages parents to talk to their baby's doctor about helping protect their baby against serious RSV lung infection with BEYFORTUS, the #1 prescribed RSV immunization for babies

该活动鼓励父母与婴儿的医生沟通，了解如何通过BEYFORTUS帮助保护婴儿免受严重的RSV肺部感染，BEYFORTUS是婴儿处方量第一的RSV免疫制剂。

MORRISTOWN, N.J.

新泽西州莫里斯敦

,

，

Sept. 8, 2026

2026年9月8日

/PRNewswire/ -- Sanofi is partnering with Emmy Award-winning actress, entrepreneur and mom Keke Palmer to help educate families about the importance of protection against serious RSV lung infection for babies. After she discussed the risks of RSV with her son's doctor, Palmer's baby received BEYFORTUS.

/美通社/ -- 赛诺菲正与艾美奖获奖女演员、企业家兼母亲凯克·帕尔默合作，帮助广大家庭了解预防婴儿严重呼吸道合胞病毒（RSV）肺部感染的重要性。在与儿子的医生讨论了RSV的风险后，帕尔默的宝宝接受了BEYFORTUS注射。

®

®

(nirsevimab-alip), a monoclonal antibody approved to help prevent serious RSV lung infection in newborns and infants entering their first RSV season, as well as in children up to 24 months of age who remain at risk for severe RSV through their second season.

（nirsevimab-alip）是一种单克隆抗体，已获批准用于帮助预防新生儿和婴儿在首个呼吸道合胞病毒（RSV）流行季期间发生严重的RSV肺部感染，以及预防直至24月龄、在第二个RSV流行季期间仍存在严重RSV感染风险的儿童。

'As moms, we spend so much time preparing for our baby's arrival and thinking about how to help keep them healthy. That includes being aware of RSV and the risk it can pose during a baby's first year of life,' said

“作为母亲，我们花费大量时间为宝宝的到来做准备，并思考如何帮助他们保持健康。这包括了解呼吸道合胞病毒（RSV）以及它在宝宝出生后第一年内可能带来的风险。”

Keke Palmer

科科·帕尔默

. 'When I spoke with my son's pediatrician, we discussed options for serious RSV protection, and together we decided that BEYFORTUS was right for him. That's why I'm partnering with Sanofi to encourage parents to learn more about RSV and talk with their baby's doctor about a protection plan that works for their family.

“在与我儿子的儿科医生交流时，我们讨论了针对呼吸道合胞病毒（RSV）的严肃防护选项，并共同决定BEYFORTUS是适合他的选择。因此，我与赛诺菲合作，鼓励家长们进一步了解RSV，并与宝宝的医生讨论适合其家庭的防护方案。”

For my baby that included BEYFORTUS.'.

对我的宝宝来说，这包括 Beyfortus。

Palmer's message comes as families prepare for RSV season. RSV is a common and highly contagious virus that can affect any baby. While it often causes mild, cold-like symptoms, it can sometimes lead to serious respiratory illness and remains a leading cause of hospitalization among infants younger than one year of age in the United States.

帕尔默发表这一消息之际，正值各家庭为呼吸道合胞病毒（RSV）流行季做准备。RSV 是一种常见且传染性极强的病毒，可感染任何婴儿。虽然它通常引起类似感冒的轻微症状，但有时可能导致严重的呼吸道疾病，并且仍然是美国一岁以下婴儿住院的主要原因之一。

More than half of babies will get RSV before their first birthday..

超过一半的婴儿在一岁前会感染呼吸道合胞病毒（RSV）。

For babies entering their first RSV season, which typically runs from fall through spring in most parts of the United States, planning ahead is important. Parents of older babies who are entering their first RSV season should talk to their baby's doctor now about RSV prevention so they can avoid missing their opportunity for immunization this season.

对于即将迎来首个呼吸道合胞病毒（RSV）流行季的婴儿，提前规划至关重要。在美国大部分地区，RSV 流行季通常从秋季持续到春季。家中有即将迎来首个 RSV 流行季的大月龄婴儿的父母，应立即与宝宝的医生讨论 RSV 预防措施，以免错过本季免疫接种的机会。

Babies born during RSV season may receive BEYFORTUS at birth or at an early well-child visit..

在呼吸道合胞病毒（RSV）流行季节出生的婴儿，可能在出生时或在早期的儿童健康检查中接受BEYFORTUS。

'Our ambition is all infant protection, all season,' said

“我们的雄心是提供全方位的婴儿保护，全年无休。”

Ayman Chit, Head of North America Medical, Vaccines at Sanofi

赛诺菲北美区疫苗医学负责人艾曼·奇特

. 'RSV is unpredictable, and it's difficult to know which babies may become seriously ill, that's why it's important for parents to have conversations with their baby's doctor about RSV protection before or during the RSV season. BEYFORTUS delivers ready-made antibodies, helping to provide rapid protection against serious RSV lung infection for 5 months, the typical length of an RSV season.

呼吸道合胞病毒（RSV）具有不可预测性，难以判断哪些婴儿可能会发展为重症，因此父母在RSV流行季之前或期间与宝宝的医生沟通RSV防护措施至关重要。BEYFORTUS提供现成抗体，有助于在5个月内（即典型的RSV流行季时长）快速预防严重的RSV肺部感染。

More than 11 million parents in the US have chosen BEYFORTUS for their baby, and by partnering with Keke Palmer, we're encouraging more families to learn about RSV prevention and talk with their baby's doctor about BEYFORTUS.' .

美国已有超过1,100万父母为他们的宝宝选择了BEYFORTUS，通过与Keke Palmer合作，我们鼓励更多家庭了解呼吸道合胞病毒（RSV）的预防措施，并与宝宝的医生讨论使用BEYFORTUS。

To learn more about BEYFORTUS and serious RSV lung infection prevention, visit BEYFORTUS.com. Parents are encouraged to talk with their baby's doctor to understand if BEYFORTUS is right for their child.

如需了解更多关于BEYFORTUS及预防严重呼吸道合胞病毒（RSV）肺部感染的信息，请访问BEYFORTUS.com。建议家长与宝宝的医生沟通，了解BEYFORTUS是否适合您的孩子。

Keke Palmer is a paid spokesperson for Sanofi.

科科·帕尔默是赛诺菲的付费代言人。

About RSV

关于呼吸道合胞病毒（RSV）

RSV is a highly contagious virus that can lead to serious respiratory illness for infants. More than half of babies will get RSV before their first birthday. Most of the time RSV will cause a mild, cold-like illness. However, RSV is the most common cause of lower respiratory tract disease (LRTD), including bronchiolitis and pneumonia, in infants.

呼吸道合胞病毒（RSV）是一种传染性极强的病毒，可能导致婴儿出现严重的呼吸道疾病。超过一半的婴儿在一岁前会感染 RSV。大多数情况下，RSV 引起的症状较轻，类似普通感冒。然而，RSV 是婴儿下呼吸道疾病（LRTD），包括细支气管炎和肺炎的最常见病因。

RSV LRTD is a leading cause of hospitalization in babies under 1, with most hospitalizations for RSV occurring in healthy infants born at term. Historically in the US, an estimated 590,000 RSV cases in babies under 1 have required medical care, including physician office, urgent care, emergency room visits and hospitalizations. .

呼吸道合胞病毒（RSV）引起的下呼吸道感染是导致1岁以下婴儿住院的主要原因，大多数因RSV住院的病例发生在足月出生的健康婴儿中。在美国，据估计，每年有59万例1岁以下婴儿的RSV病例需要医疗干预，包括就诊于医生办公室、紧急护理中心、急诊室以及住院治疗。

About BEYFORTUS

关于BEYFORTUS

BEYFORTUS is a single-dose long-acting antibody designed to help prevent RSV LRTD in infants that extends through five months, the length of the typical RSV season in the US. For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of BEYFORTUS is recommended as soon as the child is stable after surgery.

BEYFORTUS 是一种单剂量长效抗体，旨在帮助预防婴儿的呼吸道合胞病毒（RSV）下呼吸道疾病（LRTD），其保护期可持续五个月，覆盖美国典型的 RSV 流行季。对于接受体外循环心脏手术的儿童，建议在术后病情稳定后尽快追加一剂 BEYFORTUS。

An additional dose of BEYFORTUS is also indicated for children up to 24 months of age, regardless of body weight, who remain vulnerable to severe RSV disease through their second RSV season. .

对于在第二个呼吸道合胞病毒（RSV）流行季期间仍易感严重RSV疾病的24月龄以下儿童，无论体重如何，也建议追加一剂BEYFORTUS。

As a long-acting antibody provided directly to newborns and infants as a single dose, BEYFORTUS offers fast-acting protection to help prevent lower respiratory tract disease caused by RSV without requiring activation of the immune system. It has demonstrated a consistent safety profile across a broad infant population.

BEYFORTUS 是一种长效抗体，以单剂形式直接提供给新生儿和婴儿，无需激活免疫系统即可提供快速起效的保护，帮助预防由呼吸道合胞病毒（RSV）引起的下呼吸道疾病。其在广泛婴儿人群中展现出一致的安全性特征。

BEYFORTUS administration can be timed to coincide with the RSV season. .

BEYFORTUS 的给药时间可与呼吸道合胞病毒（RSV）流行季相吻合。

BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world. Special designations to facilitate expedited development of BEYFORTUS were granted by several regulatory agencies, including Breakthrough Therapy Designation and Fast Track Designation from the US Food and Drug Administration; Breakthrough Therapy Designation and Priority Review designation by The China Center for Drug Evaluation under the National Medical Products Administration; access granted to the European Medicines Agency (EMA) Priority Medicines scheme and EMA accelerated assessment; Promising Innovative Medicine designation by the UK Medicines and Healthcare products Regulatory Agency; and BEYFORTUS has been named 'a medicine for prioritized development' under the Project for Drug Selection to Promote New Drug Development in Pediatrics by the Japan Agency for Medical Research and Development. .

BEYFORTUS 已在美国、欧盟、中国、日本以及全球许多其他国家获批使用。多家监管机构授予了多项特殊认定，以加速 BEYFORTUS 的开发进程，其中包括：美国食品药品监督管理局授予的“突破性疗法认定”和“快速通道认定”；中国国家药品监督管理局药品审评中心授予的“突破性疗法认定”和“优先审评认定”；欧洲药品管理局（EMA）批准的“优先药物（PRIME）计划”资格及 EMA 加速评估；英国药品和保健品监管局授予的“前景良好的创新药物”认定；以及日本医药研究开发机构在“促进儿科新药开发的药物遴选项目”中将 BEYFORTUS 列为“优先开发药物”。

INDICATION

适应症

BEYFORTUS is a prescription medicine used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in:

BEYFORTUS 是一种处方药，用于帮助预防由呼吸道合胞病毒（RSV）引起的严重肺部疾病，适用于：

Newborns and babies under 1 year of age born during or entering their first RSV season.

在首个呼吸道合胞病毒（RSV）流行季期间出生或进入该流行季的未满1岁新生儿和婴儿。

Children up to 24 months of age who remain at risk of severe RSV disease through their second RSV season.

在第二个呼吸道合胞病毒（RSV）流行季期间仍面临严重RSV疾病风险的24月龄及以下儿童。

IMPORTANT SAFETY INFORMATION

重要安全信息

Your child should not take BEYFORTUS if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in BEYFORTUS.

如果您的孩子有对尼塞韦单抗-阿利普（nirsevimab-alip）或BEYFORTUS中任何成分发生严重过敏反应的历史，则不应使用BEYFORTUS。

Before your child receives BEYFORTUS, tell your healthcare provider about all of your child's medical conditions, including if your child:

在您的孩子接受 BEYFORTUS 之前，请告知您的医疗保健提供者您孩子的所有健康状况，包括如果您的孩子：

has ever had a reaction to BEYFORTUS.

曾对BEYFORTUS产生过反应。

has bleeding or bruising problems. If your child has a problem with bleeding or bruises easily, an injection could cause a problem.

存在出血或瘀伤问题。如果您的孩子有出血倾向或容易出现瘀伤，注射可能会引发问题。

Tell your healthcare provider about all the medicines your child takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your infant should not receive a medicine called palivizumab if they have already received BEYFORTUS in the same RSV season.

请告知您的医疗保健提供者您的孩子正在服用的所有药物，包括处方药、非处方药、维生素和草本补充剂。如果您的婴儿在同一呼吸道合胞病毒（RSV）流行季已接种过BEYFORTUS，则不应再接受名为帕利珠单抗的药物。

Serious allergic reactions have happened with BEYFORTUS. Get medical help right away if your child has any of the following signs or symptoms of a serious allergic reaction:

BEYFORTUS 曾引发严重过敏反应。如果您的孩子出现以下任何严重过敏反应的体征或症状，请立即寻求医疗帮助：

swelling of the face, mouth, or tongue

面部、口腔或舌头肿胀

difficulty swallowing or breathing

吞咽或呼吸困难

unresponsiveness

无反应

bluish color of skin, lips, or under fingernails

皮肤、嘴唇或指甲下呈现青紫色

muscle weakness

肌肉无力

severe rash, hives, or itching

严重皮疹、荨麻疹或瘙痒

The most common side effects of BEYFORTUS include rash and pain, swelling, or hardness at the site of your child's injection. These are not all the possible side effects of BEYFORTUS. Call your healthcare provider if you have questions about side effects.

BEYFORTUS 最常见的副作用包括皮疹，以及儿童注射部位的疼痛、肿胀或硬结。这些并非 BEYFORTUS 所有可能的副作用。如果您对副作用有任何疑问，请联系您的医疗保健提供者。

Please see full

请查看完整内容

Prescribing Information

处方信息

, including

，包括

Patient Information

患者信息

, for more details.

，以获取更多详情。

MAT-US-2609441-v1.0-09/2026

MAT-US-2609441-v1.0-09/2026

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time..

赛诺菲是一家研发驱动、人工智能赋能的生物制药公司，致力于改善人类生活并实现强劲增长。我们凭借对免疫系统的深刻理解，研发用于治疗和保护全球数百万人的药物与疫苗，并通过创新的产品管线惠及更多人群。我们的团队秉持一个宗旨：追寻科学奇迹，改善人类生活；这激励我们应对当今最紧迫的医疗、环境和社会挑战，推动进步，为员工和我们服务的社区带来积极影响。

Sanofi is listed on EURONEXT: SAN andNASDAQ:

赛诺菲在泛欧交易所（股票代码：SAN）和纳斯达克上市

SNY

SNY

Sanofi Media Relations

赛诺菲媒体关系部

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

[email protected]

[email protected]

Evan Berland

埃文·伯兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

[email protected]

电子邮件地址：[email protected]

Léo Le Bourhis

莱奥·勒布尔希

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

[email protected]

[email protected]

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

[email protected]

[email protected]

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

[email protected]

[email protected]

Léa Ubaldi

莱娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

[email protected]

[email protected]

Ekaterina Pesheva

叶卡捷琳娜·佩舍娃

| +1 410 926 6780 |

| +1 410 926 6780 |

[email protected]

[email protected]

Sanofi Investor Relations

赛诺菲投资者关系

Thomas Kudsk Larsen

托马斯·库斯克·拉森

|+44 7545 513 693 |

|+44 7545 513 693 |

[email protected]

[email protected]

Alizé Kaisserian

阿莉泽·凯瑟里安

| +33 6 47 04 12 11 |

+33 6 47 04 12 11

[email protected]

[email protected]

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

[email protected]

[email protected]

Nathalie Pham

纳塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

[email protected]

[email protected]

Nina Goworek

尼娜·戈沃雷克

| +1 908 569 7086 |

| +1 908 569 7086 |

[email protected]

[email protected]

Thibaud Châtelet

蒂博·沙泰勒

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

[email protected]

[email protected]

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

[email protected]

[email protected]

Sanofi forward-looking statements

赛诺菲前瞻性声明

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended.

本新闻稿包含适用证券法律（包括经修订的1995年《私人证券诉讼改革法案》）所定义的前瞻性陈述。

Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as 'expect,' 'anticipate,' 'believe,' 'intend,' 'estimate,' 'plan,' 'can,' 'contemplate,' 'could,' 'is designed to,' 'may,' 'might,' 'potential,' 'objective,' 'attempt,' 'target,' 'project,' 'strategy,' 'strive,' 'desire,' 'predict,' 'forecast,' 'ambition,' 'guideline,' 'seek,' 'should,' 'will,' 'goal,' or the negative of these and similar expressions are intended to identify forward-looking statements. .

前瞻性陈述是指非历史事实的陈述。这些陈述包括对产品市场潜力及其他潜力的预测和估计，以及与之相关的基本假设；还包括对产品未来潜在事件和收入的预测。诸如“预期”、“预计”、“相信”、“打算”、“估计”、“计划”、“能够”、“考虑”、“可能”、“旨在”、“可以”、“或许”、“潜在”、“目标”、“尝试”、“瞄准”、“规划”、“战略”、“努力”、“期望”、“预测”、“展望”、“雄心”、“指导方针”、“寻求”、“应当”、“将会”、“目标”等词语，以及这些词语的否定形式或类似表达，均用于识别前瞻性陈述。

Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

尽管赛诺菲管理层认为此类前瞻性陈述所反映的预期是合理的，但提醒投资者注意，前瞻性信息和陈述受各种风险和不确定性的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与前瞻性信息和陈述中明示、暗示或预测的内容存在重大差异。

These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities' decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including 'most favored nation' pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.

这些风险、不确定性和假设包括但不限于：意外的监管行动或延误，或一般的政府监管，这些可能影响产品的可获得性或商业潜力；产品可能无法在商业上取得成功的事实；监管机构关于是否以及何时批准候选产品的决定；美国在强制降低药品价格方面的政治压力，包括为州医疗补助计划实施“最惠国”定价；研发中固有的不确定性，包括未来的临床数据以及对现有临床数据（包括上市后数据）的分析，以及意外的安全性、质量或生产问题；一般性竞争；与知识产权相关的风险及任何相关未决或未来诉讼及其最终结果；动荡的经济和市场状况；全球危机对我们、我们的客户、供应商、_vendor_ 和其他业务合作伙伴及其任何一方财务状况的影响，以及对我们员工和全球经济整体的影响。

The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Aut.

风险和不确定性还包括在美国证券交易委员会（SEC）和法国金融市场管理局公开文件中讨论或指出的不确定性。

All trademarks mentioned in this press release are the property of the Sanofi group.

本新闻稿中提及的所有商标均为赛诺菲集团的财产。

SOURCE Sanofi

来源：赛诺菲

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示